<p>二月是最短的月份，但这并不意味着收入投资者没有时间找到优秀的股票。三位《傻瓜投资》贡献者认为，他们已经找到了本月值得购买的绝佳股息股票。以下是他们看好 <strong>AbbVie</strong>(ABBV -1.23%)、<strong>Amgen</strong>(AMGN -1.42%) 和 <strong>Gilead Sciences</strong>(GILD -2.04%) 的原因。</p>
<h2>股息王者的复苏</h2>
<p><strong>Keith Speights (AbbVie)</strong>：AbbVie 一直以来都是收入投资者的长期最爱。这家大型制药公司连续 52 年增加股息（包括它作为 <strong>Abbott</strong> 的一部分时）使其有资格成为股息之王。其预期股息收益率高达 3.4%。</p>
<p>然而，曾几何时，AbbVie 可能并未被许多投资者视为绝佳选择。Humira，这家公司的顶级畅销药物，多年来在 2023 年初失去了美国专利独占权。因此，收入和利润开始下滑。</p>
<p>然而，今天的情况大为不同。Humira 的两个继任者 Skyrizi 和 Rinvoq 的业务蒸蒸日上。这两种药物在 2024 年的总销售额超过了 Humira 的峰值年销售额。AbbVie 预计它们将在 2027 年产生超过 310 亿美元的销售额。</p>
<p>这家制药公司还有其他重要的增长动力。Qulipta 和 Ubrelvy 尤其突出，这两种偏头痛疗法在 2024 年第四季度的销售额分别同比激增 76% 和 30%。</p>
<p>AbbVie 的研发管线也看起来很有前景。该公司在中期或后期临床开发中有超过 50 个项目。Tavapadon 是一个值得关注的候选药物。它最近报告了在治疗早期帕金森病方面的积极后期结果。</p>
<h2>超越近期的临床挫折</h2>
<p><strong>Prosper Junior Bakiny (Amgen)</strong>：当一家生物技术公司的股票在令人失望的二期临床试验结果后暴跌时，该怎么办？如果制药公司的前景基本不受影响，那么这是一个购买该股票的好机会。</p>
<p>这就引出了 Amgen。在 11 月，它报告了 MariTide 的中期临床试验结果，这是一种正在研发的减肥治疗药物，市场反应导致股票下跌超过 12%。</p>
<p>尽管 Amgen 已经收复了大部分损失，但该股票在过去 12 个月内仍然下跌。长期收入寻求者应该抓住机会购买其股票，因为其前景和股息计划依然稳健。</p>
<p>该公司的产品线包括 13 种年销售额超过 10 亿美元的产品。许多产品仍然是增长动力，包括用于治疗高胆固醇的 Repatha；用于治疗绝经后骨质疏松症的 Evenity；以及用于治疗甲状腺眼病的 Tepezza。</p>
<p>Amgen 还有几种年销售额尚未达到 10 亿美元的药物，但预计很快就会，包括治疗哮喘的 Tezspire。</p>
<p>这家制药公司的研发管线仍然相当丰富，包含数十个项目。尽管 MariTide 在中期临床试验中未能完全达到预期，但它仍然有可能在减肥和肥胖市场上取得成功。</p>
<p>最后，Amgen 在过去十年中将其分红提高了 201%，并提供 3.3% 的预期收益率，而 <strong>S&amp;P 500</strong> 的平均收益率约为 1.3%。尽管在过去一年中表现落后于市场，但该股票仍然是股息寻求者的绝佳选择。</p>
<h2>Gilead 是一只稳定的股息股票，具有高且不断增长的分红</h2>
<p><strong>David Jagielski (Gilead Sciences)</strong>：生物制药公司 Gilead Sciences 现在可以成为一只绝佳的股息股票，值得购买和持有。其收益率为 3.2%，是 S&amp;P 500 平均水平的两倍多。</p>
<p>该公司也在不断增加其股息。在五年内，Gilead 的季度分红从每股 0.63 美元上升至 0.77 美元——增长了 22%。对于投资者来说，找到一家可能增加分红的公司至关重要，因为这可以帮助抵消通货膨胀的影响。</p>
<p>Gilead 的业务还产生了大量的自由现金流，这不仅可以支持当前的股息，还可以为未来的分红增加铺平道路。在过去 12 个月中，该公司产生的自由现金流总计 94 亿美元，远高于同期支付的 39 亿美元的股息。</p>
<p>另一个让股息投资者喜爱 Gilead 的原因是该股票提供的稳定性。其贝塔值约为 0.20，意味着该股票通常不会随市场波动。但尽管如此，它在过去五年中仍然是一个出色的投资，增长超过 50%。</p>
<p>Gilead 拥有强大的业务，主要集中在 HIV 药物上。但该公司也在追求治疗肝病和癌症的增长机会，这使得整体投资更加多元化。它可能不是一只快速增长的制药股票，但凭借稳健的基本面和优良的股息，它可以成为今天收入寻求者的理想投资。</p>

吉利德科学

艾伯维

<p>推荐的三只二月分红股票包括艾伯维、安进和吉利德科学。艾伯维作为分红之王，拥有 3.4% 的收益率，并且其药物 Skyrizi 和 Rinvoq 的销售表现强劲。安进尽管最近股价下跌，但提供 3.3% 的收益率，并且拥有强大的产品线。吉利德科学提供 3.2% 的收益率，过去五年分红增长了 22%，得益于强劲的自由现金流和其 HIV 药物业务的稳定性。这些股票对于寻求可靠分红的收入投资者来说，具有良好的投资前景</p>

<p>February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like <strong>AbbVie</strong>(ABBV -1.23%), <strong>Amgen</strong>(AMGN -1.42%), and <strong>Gilead Sciences</strong>(GILD -2.04%).</p>
<div class="lb-trans"><p>二月是最短的月份，但这并不意味着收入投资者没有时间找到优秀的股票。三位《傻瓜投资》贡献者认为，他们已经找到了本月值得购买的绝佳股息股票。以下是他们看好 <strong>AbbVie</strong>(ABBV -1.23%)、<strong>Amgen</strong>(AMGN -1.42%) 和 <strong>Gilead Sciences</strong>(GILD -2.04%) 的原因。</p>
</div><h2>Resurging dividend royalty</h2>
<div class="lb-trans"><h2>股息王者的复苏</h2>
</div><p><strong>Keith Speights (AbbVie)</strong>: AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was part of <strong>Abbott</strong>) qualify it as a Dividend King. Its forward dividend yield is a juicy 3.4%.</p>
<div class="lb-trans"><p><strong>Keith Speights (AbbVie)</strong>：AbbVie 一直以来都是收入投资者的长期最爱。这家大型制药公司连续 52 年增加股息（包括它作为 <strong>Abbott</strong> 的一部分时）使其有资格成为股息之王。其预期股息收益率高达 3.4%。</p>
</div><p>For a while, though, AbbVie might not have been viewed as a fabulous pick by many investors. Humira, the company's top-selling drug for years, lost U.S. patent exclusivity in early 2023. As a result, revenue and profits began to sink.</p>
<div class="lb-trans"><p>然而，曾几何时，AbbVie 可能并未被许多投资者视为绝佳选择。Humira，这家公司的顶级畅销药物，多年来在 2023 年初失去了美国专利独占权。因此，收入和利润开始下滑。</p>
</div><p>However, it's a much different story today. Business is booming for Humira's two successors, Skyrizi and Rinvoq. The two drugs generated combined sales in 2024 that eclipsed Humira's peak annual sales. AbbVie projects they'll generate sales of over $31 billion in 2027.</p>
<div class="lb-trans"><p>然而，今天的情况大为不同。Humira 的两个继任者 Skyrizi 和 Rinvoq 的业务蒸蒸日上。这两种药物在 2024 年的总销售额超过了 Humira 的峰值年销售额。AbbVie 预计它们将在 2027 年产生超过 310 亿美元的销售额。</p>
</div><p>The drugmaker has other important growth drivers, too. Qulipta and Ubrelvy especially stand out, with sales for the two migraine therapies skyrocketing 76% and 30% year over year, respectively, in the fourth quarter of 2024.</p>
<div class="lb-trans"><p>这家制药公司还有其他重要的增长动力。Qulipta 和 Ubrelvy 尤其突出，这两种偏头痛疗法在 2024 年第四季度的销售额分别同比激增 76% 和 30%。</p>
</div><p>AbbVie's pipeline also looks promising. The company has over 50 programs in mid- or late-stage clinical development. Tavapadon is one candidate to watch in the near term. It recently reported positive late-stage results for the drug in treating early Parkinson's disease.</p>
<div class="lb-trans"><p>AbbVie 的研发管线也看起来很有前景。该公司在中期或后期临床开发中有超过 50 个项目。Tavapadon 是一个值得关注的候选药物。它最近报告了在治疗早期帕金森病方面的积极后期结果。</p>
</div><h2>Look past the recent clinical setback</h2>
<div class="lb-trans"><h2>超越近期的临床挫折</h2>
</div><p><strong>Prosper Junior Bakiny (Amgen):</strong> What to do when a biotech's shares fall off a cliff following disappointing phase 2 clinical trial results? If the drugmaker's prospects are largely unaffected, it's a good opportunity to buy the stock.</p>
<div class="lb-trans"><p><strong>Prosper Junior Bakiny (Amgen)</strong>：当一家生物技术公司的股票在令人失望的二期临床试验结果后暴跌时，该怎么办？如果制药公司的前景基本不受影响，那么这是一个购买该股票的好机会。</p>
</div><p>That brings us to Amgen. In November, it reported mid-stage clinical trial results for MariTide, an investigational weight loss treatment, and the market responded by sending the stock down more than 12%.</p>
<div class="lb-trans"><p>这就引出了 Amgen。在 11 月，它报告了 MariTide 的中期临床试验结果，这是一种正在研发的减肥治疗药物，市场反应导致股票下跌超过 12%。</p>
</div><p>Though Amgen has recouped much of that loss, the stock is still down over the trailing-12-month period. Long-term income seekers should take the opportunity to buy its shares since its prospects and dividend program remain robust.</p>
<div class="lb-trans"><p>尽管 Amgen 已经收复了大部分损失，但该股票在过去 12 个月内仍然下跌。长期收入寻求者应该抓住机会购买其股票，因为其前景和股息计划依然稳健。</p>
</div><p>The company's lineup features 13 products that generate over $1 billion in sales. Many of them are still growth drivers, including Repatha, to treat high cholesterol; postmenopausal osteoporosis treatment Evenity; and Tepezza, for thyroid eye disease.</p>
<div class="lb-trans"><p>该公司的产品线包括 13 种年销售额超过 10 亿美元的产品。许多产品仍然是增长动力，包括用于治疗高胆固醇的 Repatha；用于治疗绝经后骨质疏松症的 Evenity；以及用于治疗甲状腺眼病的 Tepezza。</p>
</div><p>Amgen has several other drugs that don't bring in $1 billion in annual sales yet but should soon, especially Tezspire, which treats asthma.</p>
<div class="lb-trans"><p>Amgen 还有几种年销售额尚未达到 10 亿美元的药物，但预计很快就会，包括治疗哮喘的 Tezspire。</p>
</div><p>The drugmaker's pipeline is still pretty deep and features several dozen programs. Despite MariTide not quite living up to expectations in mid-stage clinical trials, it could still go on to become successful in the weight loss and obesity markets.</p>
<div class="lb-trans"><p>这家制药公司的研发管线仍然相当丰富，包含数十个项目。尽管 MariTide 在中期临床试验中未能完全达到预期，但它仍然有可能在减肥和肥胖市场上取得成功。</p>
</div><p>Lastly, Amgen has increased its payouts by 201% in the past decade and offers a forward yield of 3.3%, compared to the <strong>S&amp;P 500</strong>'s average of about 1.3%. It may have lagged the market over the past year, but the stock is still an excellent option for dividend seekers.</p>
<div class="lb-trans"><p>最后，Amgen 在过去十年中将其分红提高了 201%，并提供 3.3% 的预期收益率，而 <strong>S&amp;P 500</strong> 的平均收益率约为 1.3%。尽管在过去一年中表现落后于市场，但该股票仍然是股息寻求者的绝佳选择。</p>
</div><h2>Gilead is a steady dividend stock with a high, growing payout</h2>
<div class="lb-trans"><h2>Gilead 是一只稳定的股息股票，具有高且不断增长的分红</h2>
</div><p><strong>David Jagielski</strong> <strong>(Gilead Sciences):</strong> Biopharmaceutical company Gilead Sciences can make for a terrific dividend stock to buy and hold right now. It yields 3.2%, which is more than twice the S&amp;P 500 average.</p>
<div class="lb-trans"><p><strong>David Jagielski (Gilead Sciences)</strong>：生物制药公司 Gilead Sciences 现在可以成为一只绝佳的股息股票，值得购买和持有。其收益率为 3.2%，是 S&amp;P 500 平均水平的两倍多。</p>
</div><p>The company has also been growing its dividend. In five years, Gilead's quarterly payout has risen from $0.63 to $0.77 per share -- that's an increase of 22%. For investors, it can be crucial to find a company that is likely to increase its payouts because that can help offset the effects of inflation.</p>
<div class="lb-trans"><p>该公司也在不断增加其股息。在五年内，Gilead 的季度分红从每股 0.63 美元上升至 0.77 美元——增长了 22%。对于投资者来说，找到一家可能增加分红的公司至关重要，因为这可以帮助抵消通货膨胀的影响。</p>
</div><p>Gilead's business also generates plenty of free cash flow, which not only can support the current dividend but also pave the way for more increases to the payout in the future. In the trailing 12 months, the company has generated free cash flow totaling $9.4 billion -- far more than the $3.9 billion in dividends it paid out during that time frame.</p>
<div class="lb-trans"><p>Gilead 的业务还产生了大量的自由现金流，这不仅可以支持当前的股息，还可以为未来的分红增加铺平道路。在过去 12 个月中，该公司产生的自由现金流总计 94 亿美元，远高于同期支付的 39 亿美元的股息。</p>
</div><p>Another reason dividend investors will love Gilead is for the stability the stock offers. It has a low beta value of around 0.20, which means that the stock generally doesn't move along with the market. But despite this, it has still made for an excellent investment, rising by more than 50% in the past five years.</p>
<div class="lb-trans"><p>另一个让股息投资者喜爱 Gilead 的原因是该股票提供的稳定性。其贝塔值约为 0.20，意味着该股票通常不会随市场波动。但尽管如此，它在过去五年中仍然是一个出色的投资，增长超过 50%。</p>
</div><p>Gilead has a robust business that centers around HIV drugs. But the company has also been pursuing growth opportunities in treating liver disease and cancer, which make this a much more diversified investment overall. It may not be a fast-growing pharma stock, but with solid fundamentals and a great dividend, it can be an ideal investment for income seekers to load up on today.</p>
<div class="lb-trans"><p>Gilead 拥有强大的业务，主要集中在 HIV 药物上。但该公司也在追求治疗肝病和癌症的增长机会，这使得整体投资更加多元化。它可能不是一只快速增长的制药股票，但凭借稳健的基本面和优良的股息，它可以成为今天收入寻求者的理想投资。</p>
</div>

2 月份值得购买的 3 只优秀的股息股票